이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

First-year sales of Samsung’s biosimilar drug Benepali top $10 million in Europe

Collected: 2017.01.31

Distributed: 2017.02.01

Source: Go Direct

Benepali, a biosimilar product of Samsung Bioepis Co., topped surprising 100 billion won ($85.7 million) in European sales last year. Biogen Inc., the distributor for Samsung Bioepis products in Europe said in a conference call last Thursday that first-year Benepali sales reached $10.6 million (about 117 billion won) last year. The drug is marketed as Brenzys in Korea.

Benepali sales surpassed 50 billion won for the first three quarters after marketing approval early last year but sales grew sharply adding another 50 billion won in the fourth quarter alone, according to Samsung Bioepis. Benepali is a biosimilar version of Enbrel to treat rheumatoid arthritis and other autoimmune diseases. The drug was approved for marketing by the European Medicines Agency (EMA) last January.

Biogen and Samsung Bioepis aim to keep up the current momentum in Europe by expanding sales and marketing efforts into Eastern Europe. They are also planning to strengthen sales of another biosimilar Flixabi launched in the third quarter of last year in Europe. Samsung Bioepis set up as a joint venture between Samsung BioLogics and Biogen in 2012 has six biosimilar drugs in the pipeline.

Biogen owns a 6.7 percent stake in Samsung Bioepis.

By Shin Chan-ok

Read in Korean

List

Previous: Stay-at-home dads on sharp increase in Korea

Next: LG Chem and Aekyung slapped with preliminary U.S. antidumping duties